Associated Genetic Biomarkers
MAGEA1 status serves as an inclusion eligibility criteria in 4 clinical trials, of which 1 is open and 3 are closed. Of the trials that contain MAGEA1 status as an inclusion criterion, 2 are phase 1 (1 open) and 2 are phase 1/phase 2 (0 open).
Trials with MAGEA1 status in the inclusion eligibility criteria most commonly target breast carcinoma and malignant solid tumor .
The most frequent alterations to serve as inclusion eligibility criteria are MAGEA1 Expression, MAGEA10 Expression, and MAGEA12 Expression .
Ima202, cyclophosphamide, fludarabine, rvv-740cta vaccine, and recombinant interleukin-2 are the most frequent therapies in trials with MAGEA1 as an inclusion criteria .
Significance of MAGEA1 in Diseases
Malignant Solid Tumor +
MAGEA1 is an inclusion criterion in 3 clinical trials for malignant solid tumor, of which 1 is open and 2 are closed. Of the trials that contain MAGEA1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (0 open) .
Breast Carcinoma +
MAGEA1 is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MAGEA1 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.